Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
China resumes flights to North Korea after a six-year pause - 2'The best gift ever': Baby is born after the rarest of pregnancies, defying all odds
- 3ADHD drugs work, but not the way experts thought
- 4Germany records first wolf bite on human since repopulation
- 5Toddler given just 3 years to live after strange symptoms makes full recovery
- Language Learning Stages: Which One Gets Your Vote?
- Irish defence minister's trip to Lebanon cancelled
- Was it a stone tool or just a rock? An archaeologist explains how scientists can tell the difference
- America's Confided in Cooler in 2024
- Vote In favor of Your Favored Treat
- AfD in Brandenburg takes back suit against the intelligence service
- Eating Brie, Gouda, cheddar may lower dementia risk, new study says
- The architect of Iran’s military survival remains defiant
- The Best 10 Innovation Developments of the Year
